Dispute over patent rights to CRISPR-Cas9 renewed by patent office Drug Target Review
The patent office has declared an interference between 10 University of California (UC) CRISPR-Cas9 patent applications.
Dispute over patent rights to CRISPR-Cas9 renewed by patent office Drug Target Review
The patent office has declared an interference between 10 University of California (UC) CRISPR-Cas9 patent applications.